First we have this:WORCESTER, Mass., Aug 4 (Reuter) - Alpha-Beta Technology Inc said Monday that preliminary
evidence of its phase III study of its Betafectin PGG-glucan drug, found a clinically significant
reduction of serious infection in patients undergoing non-colorectal gastrointestinal surgeries.
The company said one-third of the total number of patients in the study, 391 in the non-colorectal
stratum, experienced a reduction of serious post-operative infection.
Commenting on the results of the study, Spiros Jamax, Sc.D., president and chief executive of
Alpha-Beta Technology Inc., said, ``We believe this study provides the clearest evidence to date
that Betafectin will become an important product in infectious disease management.''
Jamas added, ``We plan to meet with the FDA to discuss a PLA filing based on these results.''
Then we get this:
NEW YORK, Aug 4 (Reuter) - Alpha-Beta Technology Inc shares
ABTI.O fell in pre-opening trading after it said that its Betafectin showed no statistical significance in a test to
if it could cut serious infections. Shares were trading down to 7-1/2, traders said, down from a closing price on Friday of 10-13/16. The drug cut infection in one stratum of patients, those
undergoing non-colorectal gastointestinal surgeries, but not in
the overall study.
BEFORE THE BELL - Alpha-Beta ABTI.O slips =2
In the overall study, 17 percent of the patients treated
with Betafectin suffered serious post-surgical infections
compared with 21 percent of the placebo patients, which is not
statistically significant. |
